• BARD significantly decreased HbA 1c relative to baseline at Weeks 24 and 48 • Reductions in HbA1c induced by bardoxolone methyl were driven by results in patients with abnormal HbA1c (>7.0%) at baseline
DECREASES IN WEIGHT WITH BARDOXOLONE METHYL IN OBESE PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4 AND TYPE 2 DIABETES -POST-HOC ANALYSES FROM BEACON
• Bardoxolone methyl (BARD) is an investigational medicine that activates Nrf2 and suppresses NF-κB • Nrf2 activation is reno-protective in kidney disease models 1, 2 • By activating Nrf2, BARD targets inflammatory pathways that contribute to GFR loss in chronic kidney diseases 3-5 • BARD significantly increased eGFR and significantly reduced body weight in the BEACON clinical trial 6 • While BEACON was terminated early due to imbalance in heart failure events, post-hoc analyses have identified BNP > 200 pg/ml and prior hospitalization for heart failure to be risk factors 7 Post-hoc analyses were performed to further characterize body weight reduction due to BARD treatment 
METHODS

WAIST CIRCUMFERENCE
• BARD treatment resulted in significant reductions in body weight in an obese, CKD patient population with type 2 diabetes o Magnitude and rate of weight loss was dependent on baseline BMI o Accompanied by a significant reduction in waist circumference, which was more pronounced in patients with higher baseline BMI • 24-hr urinary creatinine excretion (a proxy for muscle mass) remained unchanged with BARD-treatment • BARD treatment lead to improved glycemic control, particularly in patients with HbA 1c > 7.0% • Data are consistent with the hypothesis that reductions in body weight with BARD are associated with loss of adipose tissue rather than muscle • Although the mechanism of weight loss with BARD treatment in humans is not fully understood, it is hypothesized that BARD increases lipolysis of peripheral lipid stores and improvements in glycemic control as observed in preclinical studies BMI, kg/m 2 (mean ± SD) 33.9 ± 7.2 33.7 ± 7.1 34.3 ± 7.9 33.7 ± 6.4
HbA 1c , % (mean ± SD) 7.10 ± 1.17 7.15 ± 1.27 6.97 ± 0.97 7.36 ± 1.54
Serum creatinine, mg/dl (mean ± SD) 2.7 ± 0.6 2.7 ± 0.6 2.8 ± 0.6 2.7 ± 0.5 
